GSA Capital Partners LLP Makes New $1.97 Million Investment in Tenaya Therapeutics, Inc. $TNYA

Key Points

• GSA Capital Partners purchased 2.67 million Tenaya Therapeutics shares worth approximately $1.97 million, representing a 1.23% stake. Institutional investors collectively own 90.54% of the company.
• Analyst sentiment remains mixed but leans positive, with a consensus rating of “Moderate Buy” and an average price target of $4.00; ratings include one Strong Buy, five Buys and one Sell.
• Tenaya reported a quarterly loss of $0.20 per share, missing the $0.07 consensus estimate, while revenue of $1.11 million fell well short of the $10 million forecast. Shares opened at $0.73, near the lower end of their 12-month range.

GSA Capital Partners LLP purchased a new position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,669,033 shares of the company's stock, valued at approximately $1,973,000. GSA Capital Partners LLP owned 1.23% of Tenaya Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of TNYA. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics during the first quarter worth $50,000. AQR Capital Management LLC acquired a new position in Tenaya Therapeutics in the first quarter valued at $442,000. Woodline Partners LP lifted its holdings in Tenaya Therapeutics by 30,563.2% in the first quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock valued at $3,373,000 after buying an additional 5,896,873 shares during the period. Marshall Wace LLP bought a new stake in Tenaya Therapeutics during the second quarter valued at $90,000. Finally, Cerity Partners LLC boosted its position in Tenaya Therapeutics by 403.5% during the second quarter. Cerity Partners LLC now owns 110,336 shares of the company's stock valued at $67,000 after acquiring an additional 88,424 shares during the last quarter. 90.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen lowered Tenaya Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 6th. Weiss Ratings upgraded Tenaya Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Tenaya Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $4.00.

Tenaya Therapeutics Price Performance

Shares of NASDAQ TNYA opened at $0.73 on Monday. The firm has a market cap of $163.26 million, a PE ratio of -1.37 and a beta of 2.83. Tenaya Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.35. The company's fifty day simple moving average is $0.76 and its 200 day simple moving average is $0.76.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.13). The business had revenue of $1.11 million for the quarter, compared to analyst estimates of $10.00 million. On average, equities analysts predict that Tenaya Therapeutics, Inc. will post -0.42 earnings per share for the current year.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.

Want to see what other hedge funds are holding TNYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source